Almirall, S.A.: Almirall H1 2026 Results
Almirall (ALM) reported H1 2026 results: net sales rose 7.5% YoY to €602.7m and EBITDA increased 23.7% to €150.7m. European Dermatology net sales grew 18.1% to €341.9m, led by biologics Ebglyss (€84.5m, +88.2%) and Ilumetri (€125.2m, +10.5%). Full-year 2026 guidance reiterated: 9-12% net sales growth and €270m-€290m EBITDA.
How this was made
The 30-second read
Why it matters
Traders can use the H1 financials and reiterated 2026 Net Sales growth (9% to 12%) and EBITDA (€270MM to €290MM) to update near-term expectations and valuation models for the company’s earnings trajectory.
Market read
A guidance-reiterating H1 beat with detailed segment and biologics growth provides a fresh datapoint for estimate revisions and sentiment.
What to watch
The article does not provide cash flow, margin drivers, or any risk items (pricing, competition, reimbursement), which could temper how much the market extrapolates from H1.
Background
Almirall is a medical dermatology pharmaceutical company with key biologics including Ebglyss and Ilumetri, and a broader portfolio across dermatology indications.
Ticker impact
Almirall reported H1 2026 Net Sales up 7.5% to €602.7MM and EBITDA up 23.7% to €150.7MM, reiterating 2026 guidance.
Moderately positive bias for the next few sessions as traders reprice 2026 EBITDA expectations around the reiterated €270MM to €290MM range.
The article provides concrete H1 financials plus unchanged guidance, which typically drives sentiment and estimate revisions, though it is not a surprise event like an acquisition or regulatory decision.
Market effects
Reinforces demand and execution strength in medical dermatology, potentially supporting sentiment for dermatology-focused pharma peers.
Highlights continued European Dermatology growth, which may influence regional healthcare sector positioning.
Global biologics portfolio growth and R&D pipeline updates can affect broader investor appetite for dermatology innovation stories.
Counterpoint
Guidance is reiterated rather than raised, so upside may be limited if the market expected a beat beyond the stated ranges.
Key entities
- companyAlmirall, S.A.
Reported H1 2026 results and reiterated full-year 2026 guidance; highlighted European Dermatology and biologics growth.
- productEbglyss
Lebrikizumab, systemic atopic dermatitis treatment; Net Sales €84.5MM, up 88.2% YoY in H1 2026.
- productIlumetri
Tildrakizumab, systemic plaque psoriasis treatment; Net Sales €125.2MM, up 10.5% YoY in H1 2026.
- partnerCertest Biotec
Announced strategic research collaboration and licensing agreement for rare dermatologic diseases and recurrent cutaneous conditions.





